See more : Himatsingka Seide Limited (HIMATSEIDE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Avidity Biosciences, Inc. (RNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avidity Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Canadian Natural Resources Limited (CNQ) Income Statement Analysis – Financial Results
- China Development Financial Holding Corporation (2883.TW) Income Statement Analysis – Financial Results
- Anupam Rasayan India Limited (ANURAS.BO) Income Statement Analysis – Financial Results
- PICC Property and Casualty Company Limited (2328.HK) Income Statement Analysis – Financial Results
- Master Style Public Company Limited (MASTER.BK) Income Statement Analysis – Financial Results
Avidity Biosciences, Inc. (RNA)
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9.56M | 9.22M | 9.33M | 6.79M | 2.32M | 379.00K |
| Cost of Revenue | 2.10M | 1.39M | 639.00K | 37.60M | 14.54M | 8.44M |
| Gross Profit | 7.46M | 7.84M | 8.69M | -30.82M | -12.22M | -8.06M |
| Gross Profit Ratio | 78.02% | 84.96% | 93.15% | -454.03% | -526.95% | -2,125.86% |
| Research & Development | 190.97M | 150.40M | 101.18M | 37.60M | 14.54M | 8.44M |
| General & Administrative | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.19M | 37.73M | 26.20M | 13.46M | 5.11M | 2.44M |
| Other Expenses | 0.00 | 4.92M | 42.00K | -78.00K | 0.00 | 0.00 |
| Operating Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Cost & Expenses | 245.16M | 188.14M | 127.38M | 51.06M | 19.65M | 10.88M |
| Interest Income | 23.97M | 4.98M | 104.00K | 206.00K | 7.39M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 209.00K | 7.39M | 718.00K |
| Depreciation & Amortization | 2.10M | 1.39M | 639.00K | 373.00K | 597.00K | 383.00K |
| EBITDA | -233.50M | -177.53M | -117.41M | -43.77M | -16.75M | -10.12M |
| EBITDA Ratio | -2,442.44% | -1,939.65% | -1,265.83% | -652.38% | -732.38% | -2,668.87% |
| Operating Income | -235.60M | -178.91M | -118.05M | -44.28M | -17.33M | -10.50M |
| Operating Income Ratio | -2,464.41% | -1,939.65% | -1,265.83% | -652.38% | -747.39% | -2,769.92% |
| Total Other Income/Expenses | 23.38M | 4.92M | 42.00K | -78.00K | -7.40M | -718.00K |
| Income Before Tax | -212.22M | -174.00M | -118.01M | -44.36M | -24.73M | -11.22M |
| Income Before Tax Ratio | -2,219.87% | -1,886.33% | -1,265.38% | -653.53% | -1,066.58% | -2,959.37% |
| Income Tax Expense | 0.00 | -4.92M | -639.00K | -373.00K | 7.39M | 718.00K |
| Net Income | -212.22M | -169.08M | -117.37M | -43.98M | -32.12M | -11.93M |
| Net Income Ratio | -2,219.87% | -1,833.01% | -1,258.52% | -648.03% | -1,385.12% | -3,148.81% |
| EPS | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| EPS Diluted | -2.91 | -3.24 | -2.83 | -2.03 | -0.86 | -0.58 |
| Weighted Avg Shares Out | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
| Weighted Avg Shares Out (Dil) | 73.01M | 52.16M | 41.43M | 21.66M | 37.51M | 20.68M |
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Oct. 23, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2023, the Human Capital Management Committee of...
Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society
SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 25, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2023, the Human Capital...
Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community leaders, patients, caregivers, and legislators in educational briefing to highlight...
Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference
SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster...
Avidity Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following...
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2023, the Human Capital Management Committee of...
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.92 per share a year ago.
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights
Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering...
Source: https://incomestatements.info
Category: Stock Reports